Stocktube video
08/02/2012

Allocate Software CEO says he feels "comfortable" with broker targets for FY profit

View full size
Additional Information
Market: AIM
Sector: Software & Computer Services
EPIC: ALL
Latest Price: 76.00p  (-0.65% Descending)
52-week High: 84.00p
52-week Low: 64.00p
Market Cap: 48.52M
1 year chart
1 day chart
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Allocate Software
www.allocate-software.co.uk

Allocate Software plc is the leading workforce optimisation software applications provider for world-wide organisations with large, multi-skilled workforces. Using MAPS, Allocate Software’s workforce optimisation software application, organisations can deploy the right people with the right skills, to the right place at the right time, allowing Allocate Software’s customers to match operational demands with workforce supply.  

With Corporate headquarters in London, regional offices in the UK, Sweden, USA, Australia, Malaysia, Allocate Software provide services and support to an international customer base across Europe, North America and Asia Pacific.  

Allocate Software plc is quoted on the London Stock Exchange (AIM: ALL). For further information please visit www.allocatesoftware.com.

Pdf

Allocate Software grows underlying revenues

6th Feb 2012, 8:05 am by Philip Whiterow Another eleven NHS trusts took Allocate’s core HealthRoster software in the first half to make 143 in total.
Staff rostering specialist Allocate Software (LON:ALL) said today underlying revenues grew in its latest half-year despite disruption to its primary care business due to NHS reforms.

Revenues overall rose to £16 million from £15.9 million in the half year to November, with underlying sales up by 15% excluding acquisitions and a £3 million contract in Australia that came through this time in the previous year.

The absence of that contract meant underlying profits fell from £3.8 million to £1.6 million, while the impact of NHS changes on primary care trusts (PCTs) meant Allocate also wrote down the value of its Dynamic Change business by £3.9 million.

That charge, plus costs for acquisitions Zircadian and Rosteron and the absence of the Australian contract meant an overall loss of £6.57 million for the half year.

Chief executive Ian Bowles said: “Our UK Healthcare business is performing at a level that is satisfactory given the continuing debate about restructuring changes in the NHS. We expect this year to secure a similar number of HealthRoster agreements to those contracted last year and the recently acquired Zircadian business is performing in line with our expectation.“

He added that the group had taken a number of initiatives to revitalise Dynanic Change and to leverage its strength in Acute Trusts. 

“These initiatives are progressing well, momentum is building and I am confident that this business will continue to recover,” he added.

Allocate’s defence arm also recently secured an extension to its multi-million pound contract with the Australian Defence Force, which will contribute to full year revenues. 

Licence revenue in the first half overall was £5.4m (2010: £7.7m), while services and support revenue grew by 29% to £10.6m (2010: £8.2m).

Another eleven NHS trusts took Allocate’s core HealthRoster software in the first half to make 143 in total, with three more extending their contracts.

“The continued organic growth and momentum across the enlarged group makes for a confident outlook for the rest of the year. The broad geographical customer base that Allocate now has enables us to maintain this confidence in our current outlook, notwithstanding the prevailing economic environment,” Bowles added.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.